CBC Group redefines CNS care in China with UCB portfolio acquisition
Singapore-based CBC Group, Asia’s largest healthcare-dedicated asset management firm, has finalized its strategic acquisition of UCB’s mature neurology and allergy business in China. In partnership ... Read More
UCB to divest mature neurology and allergy portfolio in China for $680m to CBC Group and Mubadala
UCB, a Belgian biopharmaceutical company, has announced the divestment of its mature neurology and allergy portfolio in China for $680 million, marking a strategic shift ... Read More
UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global biopharmaceutical company, shared promising 48-week post-hoc analyses ... Read More
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107
Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer's Disease drug candidate (AD drug candidate) ... Read More
Amgen and UCB resubmit BLA for EVENITY to transform osteoporosis treatment in postmenopausal women
Amgen, in collaboration with UCB, has announced the resubmission of the biologics license application (BLA) for their osteoporosis drug candidate, EVENITY (romosozumab), to the US ... Read More